Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer

Cancer J. 2020 Jan/Feb;26(1):21-28. doi: 10.1097/PPO.0000000000000428.

Abstract

Androgen deprivation therapy in combination with definitive radiation therapy is a standard of care for both intermediate-/high-risk localized prostate, locally advanced prostate cancer. Newer hormonal therapies have shown promising results in patients with castration-resistant disease and are now being investigated in early stages, in combination with radiation therapy. In this section, we review the body of evidence elucidating the mechanism of synergy and immune modulation effect of androgen deprivation therapy and radiation therapy, summarize the pivotal studies supporting its use in the nonmetastatic setting, and present the ongoing studies who will likely shape the management of locally advanced disease, in the upcoming years.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Apoptosis / drug effects
  • Apoptosis / immunology
  • Apoptosis / radiation effects
  • Autophagy / drug effects
  • Autophagy / genetics
  • Autophagy / immunology
  • Autophagy / radiation effects
  • Chemoradiotherapy / methods*
  • DNA Damage / immunology
  • DNA Damage / radiation effects
  • Disease-Free Survival
  • Evidence-Based Medicine / methods
  • Humans
  • Male
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm Staging
  • Prognosis
  • Progression-Free Survival
  • Prostate / drug effects
  • Prostate / immunology
  • Prostate / pathology
  • Prostate / radiation effects
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / therapy*
  • Randomized Controlled Trials as Topic
  • Risk Assessment / methods
  • Time Factors
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / immunology
  • Tumor Microenvironment / radiation effects

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal